IP Library Granted Patent US 11,549,103
Granted Patent B2
US 11,549,103 · App. 16/856,841 · Granted Jan 10, 2023

Recombinant microorganisms and methods of use thereof

Inventors: Shilpa Nagaraju (Skokie, IL); Bakir Al-Sinawi (Sydney, AU); Sashini De Tissera (Skokie, IL); Michael Koepke (Skokie, IL)
Assignee: LanzaTech NZ, Inc.
C12N9/0006C12N15/52C12P7/065C12P7/18C12P7/54Y02E50/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,549,103
App. No.
16/856,841
Granted
Jan 10, 2023
Kind
B2
Abstract

Provided is a method of producing a product by culturing a carboxydotrophic acetogenic bacterium with a disrupting mutation in a lactate dehydrogenase enzyme in the presence of a substrate comprising CO, CO 2 , and/or H 2 . Preferably, the disrupting mutation reduces or eliminates the expression or activity of the enzyme such that the bacterium produces a reduced amount of lactate or no lactate.

Claims (11)

1. A method of producing a product comprising culturing a carboxydotrophic acetogenic bacterium comprising a disrupting mutation in a lactate dehydrogenase enzyme in the presence of a substrate comprising CO, CO 2 , and/or H 2 whereby the bacterium produces a product selected from the group consisting of ethanol, 2,3-butanediol, formate, pyruvate, succinate, valine, leucine, isoleucine, malate, fumarate, 2-oxogluterate, citrate, and citramalate.

2. The method of claim 1 , wherein the disrupting mutation reduces or eliminates the expression or activity of the enzyme.

3. The method of claim 1 , wherein the disrupting mutation is a deletion of the lactate dehydrogenase enzyme or an inactivating mutation in the lactate dehydrogenase enzyme.

4. The method of claim 1 , wherein the bacterium produces a reduced amount of lactate compared to a parental bacterium.

5. The method of claim 1 , wherein the bacterium produces substantially no lactate.

6. The method of claim 1 , wherein the product is ethanol.

7. The method of claim 1 , wherein the bacterium produces an increased amount of the product compared to a parental bacterium.

8. The method of claim 7 , wherein the product is selected from ethanol, 2,3-butanediol, formate, pyruvate, succinate, valine, leucine, isoleucine, malate, fumarate, 2-oxogluterate, citrate, and citramalate.

9. The method of claim 8 , wherein the product is ethanol.

10. The method of claim 1 , wherein the bacterium comprises a Wood-Ljungdahl pathway.

11. The method of claim 1 , wherein the bacterium is derived from a parental bacterium selected from the group consisting of Clostridium autoethanogenum, Clostridium ljungdahlii , and Clostridium ragsdalei.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2023
From: NAGARAJU, SHILPA; AL-SINAWI, BAKIR; DE TISSERA, SASHINI; KOEPKE, MICHAEL
To: LANZATECH NZ, INC.
Reel/Frame 062467/0588 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2022
From: NAGARAJU, SHILPA; AL-SINAWI, BAKIR; DE TISSERA, SASHINI; KOEPKE, MICHAEL
To: LANZATECH NEW ZEALAND LIMITED
Reel/Frame 061959/0876 →
RELEASE OF SECURITY INTEREST Recorded May 9, 2022
From: VENTURE LENDING & LEASING VII, INC.; VENTURE LENDING & LEASING VIII, INC.
To: LANZATECH NEW ZEALAND LIMITED; LANZATECH, INC.; LANZATECH FREEDOM PINES BIOREFINERY LLC; LANZATECH HONG KONG LIMITED; LANZATECH PRIVATE LIMITED; LANZATECH UK LIMITED
Reel/Frame 059910/0789 →
CHANGE OF NAME Recorded Apr 18, 2022
From: LANZATECH NEW ZEALAND LIMITED
To: LANZATECH NZ, INC.
Reel/Frame 059724/0290 →
SECURITY INTEREST Recorded Jun 11, 2020
From: LANZATECH NEW ZEALAND LIMITED; LANZATECH, INC.; LANZATECH FREEDOM PINES BIOREFINERY LLC; LANZATECH HONG KONG LIMITED; LANZATECH PRIVATE LIMITED; LANZATECH UK LIMITED
To: VENTURE LENDING & LEASING VII, INC.; VENTURE LENDING & LEASING VIII, INC.
Reel/Frame 052914/0558 →